san diego website internet marketing web site design search engine creative internet art design director specialist expert
You need to upgrade your Flash Player This is replaced by the Flash content. Place your alternate content here and users without the Flash plugin or with Javascript turned off will see this. Content here allows you to leave out noscript tags.
patient portal, visit

Medical Care with Quality, Saviers Medical Group

Clinical Trial for High Cholesterol in patients who have recently experienced a Heart Attack or Unstable Angina (unexpected chest pain)

ODYSSEY Outcomes:

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recently experienced an Acute Coronary Syndrome.

ODYSSEY Outcomes is a worldwide clinical research study evaluation the ability of an investigational drug, called alirocumab 9also known as SAR236553), to lower LDL cholesterol and prevent  heart attacks or strokes in people who have coronary heart disease (CHD). About 18,000 participants will be enrolled at 1400 research sites in 48 countries.

For individuals with high cholesterol, the primary goal of treatment is to reduce LDL-cholesterol level and prevent the occurrence of a coronary event such as a heart attack or stroke. Statin therapy is the current standard treatment. However, not all individuals can take statins, and not everyone receives benefit from these drugs. In addition, despite statin therapy, heart attacks and strokes can still occur.
The ODYSSEY Outcome study is being conducted to see if alirocumab can help further reduce LDL cholesterol and provide additional treatment options for patients with high cholesterol.

Alirocumab works by obstructing the action of a protein called PCSK9. This protein is secreted by the liver and increases blood levels of LDL cholesterol. Alirocumab blocks PCSK9, which may decrease blood levels of LDL cholesterol.

The study drug is considered investigational because it is being tested in this clinical research study and has not been approved by the U.S. Food and Drug Administration (FDA) or similar organizations in other countries.

You may be eligible to participate if you have:

  • Been recently hospitalized with a heart attack or unstable angina (unexpected chest pain), and
  • High cholesterol that cannot be fully controlled with current medicine.

Your study doctor will determine if you are eligible to participate in ODYSSEY Outcomes and if so, he or she will describe the study to you and if you would like to participate. Your participation is entirely voluntary.

If you decide to participate in ODYSSEY Outcomes, your study coordinator and doctor will fully explain what is expected of you as a study participant.

As an overview, you can expect that you will be asked to:

  • Take the study drug or placebo every two weeks by subcutaneous (under the skin) injection for the duration of the study.
  • Continue to take you cholesterol medication as directed.
  • Attend all study and follow-up appointments. At some of these visits, you will be asked to undergo a brief physical examination including measurements of weight, blood pressure, heart rate, urine and blood tests.

Depending on when you start and the progress of the study, your participation may last from about 2 to 6 years.

Our current clinical trials by health condition:

Type 2 Diabetes

High Cholesterol in patients who have recently experienced a Heart Attack or Unstable Angina (unexpected chest pain)

Chronic Obstructive Pulmonary Disease (Chronic Bronchitis or Emphysema)

contact us today

To make an appointment or to ask questions about our services please call us at 805-271-0708 or contact us online:

Saviers Medical Group
246 E Scott St (Beachport Center) Port Hueneme, California 93041
Phone: 805-271-0708
Fax: 805-271-0769

Hours of Operation:
Monday to Friday
9.00 AM till 5.30 PM
Saturday (by appointments only)


click here to download our forms